{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:00:18Z","timestamp":1791525618554,"version":"4.3.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T00:00:00Z","timestamp":1735516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203778"],"award-info":[{"award-number":["82203778"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-024-04145-z","type":"journal-article","created":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T13:53:41Z","timestamp":1735566821000},"page":"211-222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Anillin interacts with RhoA to promote tumor progression in anaplastic thyroid cancer by activating the PI3K\/AKT pathway"],"prefix":"10.1007","volume":"88","author":[{"given":"Shi-Tong","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai-Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Na","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Gang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Ting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2014-3813","authenticated-orcid":false,"given":"Shang-Tong","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,30]]},"reference":[{"key":"4145_CR1","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.21037\/gs.2019.10.18","volume":"9","author":"SM Ferrari","year":"2020","unstructured":"S.M. Ferrari, G. Elia, F. Ragusa, I. Ruffilli, C. La Motta, S.R. Paparo et al. Novel treatments for anaplastic thyroid carcinoma. Gland Surg. 9(1), S28\u2013S42 (2020). https:\/\/doi.org\/10.21037\/gs.2019.10.18","journal-title":"Gland Surg."},{"issue":"1","key":"4145_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jncc.2024.01.006","volume":"4","author":"B Han","year":"2024","unstructured":"B. Han, R. Zheng, H. Zeng, S. Wang, K. Sun, R. Chen, L. Li, W. Wei, J. He, Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 4(1), 47\u201353 (2024). https:\/\/doi.org\/10.1016\/j.jncc.2024.01.006","journal-title":"J. Natl. Cancer Cent."},{"issue":"5","key":"4145_CR3","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1001\/jama.2023.26348","volume":"331","author":"L Boucai","year":"2024","unstructured":"L. Boucai, M. Zafereo, M.E. Cabanillas, Thyroid cancer: a review. JAMA 331(5), 425\u2013435 (2024). https:\/\/doi.org\/10.1001\/jama.2023.26348","journal-title":"JAMA"},{"issue":"1","key":"4145_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1\u2013133 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"issue":"3","key":"4145_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1089\/thy.2020.0944","volume":"31","author":"KC Bible","year":"2021","unstructured":"K.C. Bible, E. Kebebew, J. Brierley, J.P. Brito, M.E. Cabanillas, T.J. Clark Jr. et al. 2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer. Thyroid 31(3), 337\u2013386 (2021). https:\/\/doi.org\/10.1089\/thy.2020.0944","journal-title":"Thyroid"},{"issue":"2","key":"4145_CR6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00018-020-03605-9","volume":"78","author":"NG Naydenov","year":"2021","unstructured":"N.G. Naydenov, J.E. Koblinski, A.I. Ivanov, Anillin is an emerging regulator of tumorigenesis, acting as a cortical cytoskeletal scaffold and a nuclear modulator of cancer cell differentiation. Cell Mol. Life Sci. 78(2), 621\u2013633 (2021). https:\/\/doi.org\/10.1007\/s00018-020-03605-9","journal-title":"Cell Mol. Life Sci."},{"issue":"6","key":"4145_CR7","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.devcel.2019.04.031","volume":"49","author":"S Budnar","year":"2019","unstructured":"S. Budnar, K.B. Husain, G.A. Gomez, M. Naghibosadat, A. Varma, S. Verma et al. Anillin promotes cell contractility by cyclic resetting of RhoA residence kinetics. Dev. Cell 49(6), 894\u2013906 e12 (2019). https:\/\/doi.org\/10.1016\/j.devcel.2019.04.031","journal-title":"Dev. Cell"},{"issue":"3","key":"4145_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1083\/jcb.150.3.539","volume":"150","author":"K Oegema","year":"2000","unstructured":"K. Oegema, M.S. Savoian, T.J. Mitchison, C.M. Field, Functional analysis of a human homologue of the Drosophila actin binding protein anillin suggests a role in cytokinesis. J. Cell Biol. 150(3), 539\u2013552 (2000). https:\/\/doi.org\/10.1083\/jcb.150.3.539","journal-title":"J. Cell Biol."},{"issue":"24","key":"4145_CR9","doi-asserted-by":"publisher","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-05-1507","volume":"65","author":"C Suzuki","year":"2005","unstructured":"C. Suzuki, Y. Daigo, N. Ishikawa, T. Kato, S. Hayama, T. Ito et al. ANLN plays a critical role in human lung carcinogenesis through the activation of RHOA and by involvement in the phosphoinositide 3-kinase\/AKT pathway. Cancer Res. 65(24), 11314\u201311325 (2005). https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-1507","journal-title":"Cancer Res."},{"issue":"1-2","key":"4145_CR10","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11010-014-2200-6","volume":"398","author":"W Zhou","year":"2015","unstructured":"W. Zhou, Z. Wang, N. Shen, W. Pi, W. Jiang, J. Huang et al. Knockdown of ANLN by lentivirus inhibits cell growth and migration in human breast cancer. Mol. Cell Biochem. 398(1-2), 11\u201319 (2015). https:\/\/doi.org\/10.1007\/s11010-014-2200-6","journal-title":"Mol. Cell Biochem."},{"issue":"8","key":"4145_CR11","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.18632\/aging.101510","volume":"10","author":"YF Lian","year":"2018","unstructured":"Y.F. Lian, Y.L. Huang, J.L. Wang, M.H. Deng, T.L. Xia, M.S. Zeng et al. Anillin is required for tumor growth and regulated by miR-15a\/miR-16-1 in HBV-related hepatocellular carcinoma. Aging (Albany NY) 10(8), 1884\u20131901 (2018). https:\/\/doi.org\/10.18632\/aging.101510","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"4145_CR12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s13046-019-1340-7","volume":"38","author":"A Wang","year":"2019","unstructured":"A. Wang, H. Dai, Y. Gong, C. Zhang, J. Shu, Y. Luo et al. ANLN-induced EZH2 upregulation promotes pancreatic cancer progression by mediating miR-218-5p\/LASP1 signaling axis. J. Exp. Clin. Cancer Res. 38(1), 347 (2019). https:\/\/doi.org\/10.1186\/s13046-019-1340-7","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"2","key":"4145_CR13","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1089\/thy.2016.0285","volume":"27","author":"P Weinberger","year":"2017","unstructured":"P. Weinberger, S.R. Ponny, H. Xu, S. Bai, R. Smallridge, J. Copland et al. Cell cycle M-phase genes are highly upregulated in anaplastic thyroid carcinoma. Thyroid 27(2), 236\u2013252 (2017). https:\/\/doi.org\/10.1089\/thy.2016.0285","journal-title":"Thyroid"},{"issue":"38","key":"4145_CR14","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.1021\/bi300758e","volume":"51","author":"EC Lessey","year":"2012","unstructured":"E.C. Lessey, C. Guilluy, K. Burridge, From mechanical force to RhoA activation. Biochemistry 51(38), 7420\u20137432 (2012). https:\/\/doi.org\/10.1021\/bi300758e","journal-title":"Biochemistry"},{"issue":"1779","key":"4145_CR15","doi-asserted-by":"publisher","first-page":"20180226","DOI":"10.1098\/rstb.2018.0226","volume":"374","author":"EA Brooks","year":"2019","unstructured":"E.A. Brooks, S. Galarza, M.F. Gencoglu, R.C. Cornelison, J.M. Munson, S.R. Peyton, Applicability of drug response metrics for cancer studies using biomaterials. Philos. Trans. R. Soc. Lond. B Biol. Sci. 374(1779), 20180226 (2019). https:\/\/doi.org\/10.1098\/rstb.2018.0226","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"4145_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.09.002","volume":"183","author":"S Jansen","year":"2018","unstructured":"S. Jansen, R. Gosens, T. Wieland, M. Schmidt, Paving the Rho in cancer metastasis: Rho GTPases and beyond. Pharm. Ther. 183, 1\u201321 (2018). https:\/\/doi.org\/10.1016\/j.pharmthera.2017.09.002","journal-title":"Pharm. Ther."},{"issue":"11","key":"4145_CR17","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.bcp.2011.08.021","volume":"82","author":"WB Zhong","year":"2011","unstructured":"W.B. Zhong, S.P. Hsu, P.Y. Ho, Y.C. Liang, T.C. Chang, W.S. Lee, Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho\/ROCK-mediated pathway. Biochem Pharm. 82(11), 1663\u20131672 (2011). https:\/\/doi.org\/10.1016\/j.bcp.2011.08.021","journal-title":"Biochem Pharm."},{"issue":"7","key":"4145_CR18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.3390\/ijms19071834","volume":"19","author":"WB Zhong","year":"2018","unstructured":"W.B. Zhong, Y.C. Tsai, L.H. Chin, J.H. Tseng, L.W. Tang, S. Horng et al. A synergistic anti-cancer effect of troglitazone and lovastatin in a human anaplastic thyroid cancer cell line and in a mouse xenograft model. Int. J. Mol. Sci. 19(7), 1834 (2018). https:\/\/doi.org\/10.3390\/ijms19071834","journal-title":"Int. J. Mol. Sci."},{"key":"4145_CR19","doi-asserted-by":"publisher","first-page":"9725","DOI":"10.2147\/CMAR.S261828","volume":"12","author":"F Wang","year":"2020","unstructured":"F. Wang, Z. Xiang, T. Huang, M. Zhang, W.B. Zhou, ANLN directly interacts with RhoA to promote doxorubicin resistance in breast cancer cells. Cancer Manag. Res. 12, 9725\u20139734 (2020). https:\/\/doi.org\/10.2147\/CMAR.S261828","journal-title":"Cancer Manag. Res."},{"issue":"22","key":"4145_CR20","doi-asserted-by":"publisher","first-page":"3118","DOI":"10.1038\/s41388-022-02274-1","volume":"41","author":"J Chen","year":"2022","unstructured":"J. Chen, Z. Li, X. Jia, W. Song, H. Wu, H. Zhu et al. Targeting anillin inhibits tumorigenesis and tumor growth in hepatocellular carcinoma via impairing cytokinesis fidelity. Oncogene 41(22), 3118\u20133130 (2022). https:\/\/doi.org\/10.1038\/s41388-022-02274-1","journal-title":"Oncogene"},{"issue":"3","key":"4145_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0352-0","volume":"9","author":"ST Yu","year":"2018","unstructured":"S.T. Yu, Q. Zhong, R.H. Chen, P. Han, S.B. Li, H. Zhang et al. CRLF1 promotes malignant phenotypes of papillary thyroid carcinoma by activating the MAPK\/ERK and PI3K\/AKT pathways. Cell Death Dis. 9(3), 371 (2018). https:\/\/doi.org\/10.1038\/s41419-018-0352-0","journal-title":"Cell Death Dis."},{"issue":"1","key":"4145_CR22","doi-asserted-by":"publisher","first-page":"bqac187","DOI":"10.1210\/endocr\/bqac187","volume":"164","author":"D Huang","year":"2022","unstructured":"D. Huang, Y. Zeng, H.Y. Deng, B.D. Fu, Y. Ke, J.Y. Luo et al. SYTL5 promotes papillary thyroid carcinoma progression by enhancing activation of the NF-kappaB signaling pathway. Endocrinology 164(1), bqac187 (2022). https:\/\/doi.org\/10.1210\/endocr\/bqac187","journal-title":"Endocrinology"},{"key":"4145_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3389\/fendo.2020.00535","volume":"11","author":"ST Yu","year":"2020","unstructured":"S.T. Yu, B.H. Sun, J.N. Ge, J.L. Shi, M.S. Zhu, Z.G. Wei et al. CRLF1-MYH9 interaction regulates proliferation and metastasis of papillary thyroid carcinoma through the ERK\/ETV4 axis. Front Endocrinol. (Lausanne) 11, 535 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.00535","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"1","key":"4145_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01658-x","volume":"21","author":"Z Pan","year":"2022","unstructured":"Z. Pan, T. Xu, L. Bao, X. Hu, T. Jin, J. Chen et al. CREB3L1 promotes tumor growth and metastasis of anaplastic thyroid carcinoma by remodeling the tumor microenvironment. Mol. Cancer 21(1), 190 (2022). https:\/\/doi.org\/10.1186\/s12943-022-01658-x","journal-title":"Mol. Cancer"},{"issue":"8","key":"4145_CR25","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/sj.bjc.6603578","volume":"96","author":"RF Rodrigues","year":"2007","unstructured":"R.F. Rodrigues, L. Roque, T. Krug, V. Leite, Poorly differentiated and anaplastic thyroid carcinomas: chromosomal and oligo-array profile of five new cell lines. Br. J. Cancer 96(8), 1237\u20131245 (2007). https:\/\/doi.org\/10.1038\/sj.bjc.6603578","journal-title":"Br. J. Cancer"},{"issue":"5","key":"4145_CR26","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1089\/thy.2016.0254","volume":"27","author":"B Bonhomme","year":"2017","unstructured":"B. Bonhomme, Y. Godbert, G. Perot, A. Al Ghuzlan, S. Bardet, G. Belleannee et al. Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases. Thyroid 27(5), 682\u2013692 (2017). https:\/\/doi.org\/10.1089\/thy.2016.0254","journal-title":"Thyroid"},{"issue":"17","key":"4145_CR27","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.1158\/1078-0432.CCR-17-1043","volume":"23","author":"S Kotian","year":"2017","unstructured":"S. Kotian, L. Zhang, M. Boufraqech, K. Gaskins, S.K. Gara, M. Quezado et al. Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 inhibits thyroid cancer growth and metastases. Clin. Cancer Res. 23(17), 5044\u20135054 (2017). https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1043","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"4145_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04538-0","volume":"21","author":"Y Zhong","year":"2023","unstructured":"Y. Zhong, F. Yu, L. Yang, Y. Wang, L. Liu, C. Jia et al. HOXD9\/miR-451a\/PSMB8 axis is implicated in the regulation of cell proliferation and metastasis via PI3K\/AKT signaling pathway in human anaplastic thyroid carcinoma. J. Transl. Med 21(1), 817 (2023). https:\/\/doi.org\/10.1186\/s12967-023-04538-0","journal-title":"J. Transl. Med"},{"key":"4145_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114500","volume":"238","author":"Y Zhang","year":"2022","unstructured":"Y. Zhang, Z. Xing, T. Liu, M. Tang, L. Mi, J. Zhu et al. Targeted therapy and drug resistance in thyroid cancer. Eur. J. Med Chem. 238, 114500 (2022). https:\/\/doi.org\/10.1016\/j.ejmech.2022.114500","journal-title":"Eur. J. Med Chem."},{"issue":"1","key":"4145_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e23522","volume":"10","author":"M Gao","year":"2024","unstructured":"M. Gao, Z. Tuo, Z. Jiang, Z. Chen, J. Wang, Dysregulated ANLN reveals immune cell landscape and promotes carcinogenesis by regulating the PI3K\/Akt\/mTOR pathway in clear cell renal cell carcinoma. Heliyon 10(1), e23522 (2024). https:\/\/doi.org\/10.1016\/j.heliyon.2023.e23522","journal-title":"Heliyon"},{"issue":"8","key":"4145_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04063-2","volume":"12","author":"E Guo","year":"2021","unstructured":"E. Guo, X. Mao, X. Wang, L. Guo, C. An, C. Zhang et al. Alternatively spliced ANLN isoforms synergistically contribute to the progression of head and neck squamous cell carcinoma. Cell Death Dis. 12(8), 764 (2021). https:\/\/doi.org\/10.1038\/s41419-021-04063-2","journal-title":"Cell Death Dis."},{"issue":"1","key":"4145_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13005-021-00269-z","volume":"17","author":"B Wang","year":"2021","unstructured":"B. Wang, X.L. Zhang, C.X. Li, N.N. Liu, M. Hu, Z.C. Gong, ANLN promotes carcinogenesis in oral cancer by regulating the PI3K\/mTOR signaling pathway. Head. Face Med 17(1), 18 (2021). https:\/\/doi.org\/10.1186\/s13005-021-00269-z","journal-title":"Head. Face Med"},{"issue":"2","key":"4145_CR33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/08941939.2020.1850939","volume":"35","author":"Y Liu","year":"2022","unstructured":"Y. Liu, P. Cao, F. Cao, S. Wang, Y. He, Y. Xu et al. ANLN, regulated by SP2, promotes colorectal carcinoma cell proliferation via PI3K\/AKT and MAPK signaling pathway. J. Invest Surg. 35(2), 268\u2013277 (2022). https:\/\/doi.org\/10.1080\/08941939.2020.1850939","journal-title":"J. Invest Surg."},{"issue":"3","key":"4145_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41388-023-02889-y","volume":"43","author":"H Lasolle","year":"2024","unstructured":"H. Lasolle, A. Schiavo, A. Tourneur, P. Gillotay, B. de Faria da Fonseca, L. Ceolin et al. Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids. Oncogene 43(3), 155\u2013170 (2024). https:\/\/doi.org\/10.1038\/s41388-023-02889-y","journal-title":"Oncogene"},{"key":"4145_CR35","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.semcancer.2020.06.013","volume":"79","author":"P Fallahi","year":"2022","unstructured":"P. Fallahi, S.M. Ferrari, G. Elia, F. Ragusa, A. Patrizio, S.R. Paparo et al. Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin. Semin Cancer Biol. 79, 203\u2013216 (2022). https:\/\/doi.org\/10.1016\/j.semcancer.2020.06.013","journal-title":"Semin Cancer Biol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04145-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-04145-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-04145-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T07:45:14Z","timestamp":1742802314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-04145-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,30]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["4145"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-04145-z","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,30]]},"assertion":[{"value":"8 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethics approval and consent to participate patient data we used were acquired by publicly available datasets that were collected with patients\u2019 informed consent. The clinical samples used in this study was approved by the Ethics Committee of Nanfang Hospital. The study was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}